LPCN 2401 – Obesity Management
Quality weight loss
Preserve lean mass
Amplify fat loss
Product Candidate: LPCN 2401
Prioritizing fat loss and lean mass preservation in healthy weight loss
Product Attributes:
LPCN 2401 comprises a novel, liver friendly, physiological regulator of myostatin that indirectly inhibits its expression and signaling via Androgen Receptor-mediated pathways, transcriptional repression, and crosstalk with anabolic factors. LPCN 2401 is currently under development as an adjunct to Incretin Mimetics (e.g. GLP-1 agonists) for quality weight loss via improved body composition or as a monotherapy post cessation of incretin mimetic use in diabesity management. LPCN 2401 is designed for once daily administration, consistent with the ongoing development of patient friendly, once-a-day incretin mimetic treatments.
Data from preclinical and clinical studies support the potential of LPCN 2401 to prevent the loss of lean mass and physical function associated with incretin mimetic therapies.
About Indication:
In the US, ~110M adults suffer from diabetes, and obesity and overweight is a growing epidemic. Approved incretin mimetics, such as GLP-1 agonists for diabetes and chronic weight management, are experiencing unprecedented demand and usage in the US, and are projected to reach 30 million users by 2030.
Obesity is a chronic disease characterized by excess adiposity. Excess adiposity is associated with an increased risk of death and major comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, nonalcoholic steatohepatitis, gallbladder disease, osteoarthritis of the knee, sleep apnea, and some cancers. The pathogenesis of obesity involves the interaction of genetic, environmental, and behavioral factors. Patients with overweight also represent a patient population at increased health risk from excess adiposity.
The rapid weight loss observed with the approved incretin mimetics for weight management includes unwanted lean mass loss; up to 40% of the patient’s total weight loss is from lean mass (bone and muscle). The ~24M obese elderly adults are most vulnerable to losing additional lean mass and functionality with GLP-1 agonist use.
A major drawback of approved GLP-1 receptor agonists use is loss of lean mass. Lean mass matters because it improves metabolic health, strength and functionality and hormonal balance. Loss of lean mass has multiple negative health implications including reduced physical function, lowered basal metabolism, and increased risk of injury.
In elderly patients (≥60 years old), the equivalent of ~8 years of age-related decline in physical function was seen after just four months of incretin mimetic use. Moreover, discontinuation of incretin mimetic therapies frequently results in a rapid regain in weight, potentially mostly as fat mass.
There is a significant unmet need for an oral, efficacious adjunct treatment option to enable healthy chronic weight management through improved body composition that predominantly reduces fat mass while preserving lean mass, in order to reduce fracture risk and maintain functionality. Moreover, there is a need for a chronic pharmacotherapy option to maintain weight and diabetes remission, prevent fat rebound, and improve lean mass upon cessation of incretin mimetic therapy.